Blood-Brain Barrier SPM Shuttle System
Quality Report Card click to collapse
From Analysis:
Neuroinflammation resolution mechanisms and pro-resolving mediators
SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation resolution. Are resolution failures druggable?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Description
Mechanistic Foundation
Specialized pro-resolving mediators (SPMs) - including resolvins, protectins, and maresins - are endogenous lipid mediators that actively terminate neuroinflammation and promote tissue repair. Unlike anti-inflammatory drugs that merely block inflammatory pathways, SPMs actively stimulate resolution programs: clearance of apoptotic debris, restoration of blood-brain barrier integrity, and regeneration of damaged neural tissue. In Alzheimer's disease, SPM biosynthesis is impaired and brain levels are dramatically reduced, contributing to chronic unresolved neuroinflammation.
Figures & Visualizations
3D Protein Structure
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
Dimension Scores
Legacy Card View — expandable citation cards
✓ Supporting Evidence 16
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain ba… HIGH▼
Validates TfR as BBB shuttle for therapeutic payloads
Demonstrates engineered TfR-binding enables CNS delivery
Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin recep… HIGH▼
Nanobody platform for TfR-mediated transcytosis
Specialized pro-resolving mediators reduce brain inflammation and amyloid pathology in Alzheimer's disease mod… HIGH▼
SPMs show efficacy in AD models but require improved delivery
Human biomarker evidence for SPM deficit in AD
Mechanism of SPM pro-resolution effects
Genetic link between SPM synthesis and AD susceptibility
Pharmacokinetic advantage of TfR shuttle system
The lysosome-targeting chimera (LYTAC) strategy provided a very powerful tool for the degradation of membrane proteins. However, the synthesis of LYTACs, antibody-small molecule conjugates, is challenging. The ability of antibody-based LYTACs to penetrate solid tumor is limited as well, especially to cross the blood-brain barrier (BBB). Here, we propose a covalent chimeric peptide-based targeted degradation platform (Pep-TACs) by introducing a long flexible aryl sulfonyl fluoride group, which allows proximity-enabled cross-linking upon binding with the protein of interest. The Pep-TACs platform facilitates the degradation of target proteins through the mechanism of recycling transferrin receptor (TFRC)-mediated lysosomal targeted endocytosis. Biological experiments demonstrate that covalent Pep-TACs can significantly degrade the expression of PD-L1 on tumor cells, dendritic cells and macrophages, especially under acidic conditions, and markedly enhance the function of T cells and tumor phagocytosis by macrophages. Furthermore, both in anti-PD-1-responsive and -resistant tumor models, the Pep-TACs exert significant anti-tumor immune response. It is noteworthy that Pep-TACs can cross the BBB and prolong the survival of mice with in situ brain tumor. As a proof-of-concept, this study introduces a modular TFRC-based covalent peptide degradation platform for the degradation of membrane protein, and especially for the immunotherapy of brain tumors.
Antibodies to transferrin receptor (TfR) have potential use for therapeutic entry into the brain. We have shown that bispecific antibodies against TfR and β-secretase (BACE1 [β-amyloid cleaving enzyme-1]) traverse the blood-brain barrier (BBB) and effectively reduce brain amyloid β levels. We found that optimizing anti-TfR affinity improves brain exposure and BACE1 inhibition. Here we probe the cellular basis of this improvement and explore whether TfR antibody affinity alters the intracellular trafficking of TfR. Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affinity binding to TfR caused a dose-dependent reduction of brain TfR levels. In vitro live imaging and colocalization experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR to lysosomes and thus induced the degradation of TfR, an observation which was further confirmed in vivo. Importantly, high-affinity anti-TfR dosing induced reductions in brain TfR levels, which significantly decreased brain exposure to a second dose of low-affinity anti-TfR bispecific. Thus, high-affinity anti-TfR alters TfR trafficking, which dramatically impacts the capacity for TfR to mediate BBB transcytosis.
Systemic chronic inflammation (SCI) is a key driver of non-communicable diseases. Early-life stressors disrupt intestinal homeostasis, promoting SCI, but the mechanisms are unclear. Using translational models, we identify dysregulated iron homeostasis as a pivotal disruptor of intestinal barrier integrity. Single-cell profiling reveals that neutrophils and macrophages mediate iron-dependent mucosal defense. Stress induces iron overload in gut epithelial cells and macrophages, a process governed by the transcription factor MITF. MITF-mediated iron dysregulation in macrophages is associated with neutrophil recruitment to the lamina propria, concomitant with elevated levels of the CXCL8, synchronizing with hepatic inflammatory and metabolic dysregulation via the gut-liver axis. Mechanistically, abnormal iron homeostasis couples with interferon signaling, and MITF modulates iron-related genes (FTH1, TFRC, and FRRS1). Therapeutic mitigation of iron dyshomeostasis preserves barrier function and attenuates systemic inflammation. Our findings identify MITF as a key regulator of gut-liver inflammatory cascades and nominate abnormal iron homeostasis as a target for early-life inflammatory disorders.
Early hypoxia-induced secretome remodeling reveals adaptive mechanisms and biomarkers of blood-brain barrier d… MEDIUM▼
Reversible disruption of the blood-brain barrier (BBB) occurs within hours after the onset of ischemic stroke (IS), offering a critical window for therapeutic intervention. However, the molecular characteristics and their potential as circulating biomarkers associated with this transient phase of BBB dysfunction remain poorly defined. To elucidate these mechanisms, we employed an oxygen-glucose deprivation (OGD) model in human cerebral microvascular endothelial cells (hCMEC/D3) to simulate early ischemic stress, and systematically profiled their secreted proteome and metabolome. By comparing with non-brain-derived human umbilical vein endothelial cells (HUVECs), we identified brain endothelium-specific hypoxic response signatures. These molecules were significantly enriched in pathways related to metabolic reprogramming, antioxidant defense, and epigenetic regulation pathways, indicating a coordinated adaptive response to preserve BBB homeostasis. Furthermore, integrative multi-omics analysis revealed 14 protein-metabolite pairs with potential functional synergy. Based on a multi-criteria screening strategy including brain specificity, functional relevance, and secretory potential, we prioritized 10 candidate circulating biomarkers: ALDH2, ITGA5, KYNU, TFRC, CD44, COL1A2, HEXB, HSPG2, THBS4, and DLD. Preliminary validation using serum from acute IS (AIS) patients and healthy controls showed significantly altered levels of ALDH2, ITGA5, KYNU, and TFRC, with TFRC exhibiting pro
Ferrostatin-1 alleviates experimental cerebral malaria by regulating immune cell functions and brain endotheli… MEDIUM▼
Cerebral malaria (CM), a life-threatening complication of Plasmodium falciparum infection, is characterized by dysregulated immune responses and blood-brain barrier (BBB) damage. In this study, we found that iron metabolic disorders occurred in the spleen and brain tissues in response to Plasmodium berghei ANKA (PbA) infection in a murine CM model. PbA infection promoted lipid peroxidation and induced ferroptosis, manifested as the accumulation of iron ion, elevation of reactive oxygen species and lipid peroxide, upregulated expression of the ferroptosis-related protein TFRC and ACSL4, and downregulated expression of SLC7A11 and GPX4. Ferrostatin-1 (Fer-1), is widely used as a reference compound as a synthetic radical-trapping antioxidant, which inhibits ferroptosis by suppressing lipid peroxide formation. Intervention with Fer-1 ameliorated iron metabolic disorders, reduced lipid peroxidation, decreased parasitemia, extended survival time, alleviated neurological symptoms, and improved BBB integrity. Mechanistically, Fer-1 exerted dual-axis regulation: firstly, enhancing the antigen-presenting capacity of dendritic cells (DCs) by upregulating MHC II, CD80/86, promoting M1 polarization of macrophages, modulating CD4+ T cell responses to increase IFN-γ+ Th1 cells and Treg cell proportions for balancing pro-inflammatory and anti-inflammatory reactions; secondly inhibiting ferroptosis in brain microvascular endothelial cells, downregulating chemokines CXCL9/CXCL10 and adhesion m
A humanized transferrin receptor 1-transferrin model supports functional iron homeostasis and therapeutic deli… MEDIUM▼
The transferrin receptor 1 (TfR1)-transferrin (TF) axis is central to iron homeostasis and represents a validated route for delivering biologics across the blood-brain barrier (BBB). We developed human-specific anti-TfR1 nanobodies (NewroBus) that exploit this pathway, but their lack of cross-reactivity with rodent TfR1 limits conventional preclinical testing. To overcome this, we generated knock-in rats in which the coding sequences of the endogenous Tfrc and Tf genes were replaced with their human counterparts, producing animals that express human TfR1 and/or human TF under physiological control. Rats homozygous for both humanized alleles were viable and fertile, indicating functional replacement of their rodent orthologs but exhibited erythropoietic abnormalities and altered iron distribution-reduced splenic and increased hepatic iron-suggesting incomplete compensation. In contrast, heterozygous rats displayed only mild, subclinical microcytosis and hypochromia while maintaining normal BBB integrity and near-physiological iron homeostasis. Using these heterozygous humanized Tfrc rats, we demonstrated that a biologic engineered to engage human TfR1, NewroBus, fused to a therapeutic payload such as TNFα-neutralizing nanobodies, achieved significant BBB penetration and central nervous system exposure. These results validate the translational relevance of this model for studying TfR1-mediated drug delivery. Overall, the humanized TfR1-TF axis is compatible with life and system
Dietary Iron Deficiency in Adult Mice Increases Brain Uptake of High-Affinity, Anti-Transferrin Receptor Antib… MEDIUM▼
Brain capillary endothelial cells (BCECs) express transferrin receptor 1 (TfR1) to ensure sufficient iron transport into the brain. Our main objective was to examine adult mice subjected to dietary iron deficiency (ID) for possible changes in the content of TfR1 in BCECs and the influence thereof on the uptake and possible transport across the blood-brain barrier (BBB) of high-affinity, rat anti-mouse transferrin receptor IgG2a antibody (clone RI7217) targeting the TfR1. We subjected adult, female mice to dietary ID for 8 weeks. Iron and copper were measured using inductively coupled plasma mass spectrometry (ICP-MS) in various tissues, including total brain, and fractions of brain tissue separated to contain a capillary enriched fraction ("capillary fraction") and a post-capillary, non-endothelial-containing brain parenchymal fraction ("brain fraction"). Possible effects of ID on the cerebral angioarchitecture were estimated using 3D confocal microscopy of optically cleared brain samples labeled using intravenous injection of wheat germ agglutinin with subsequent machine learning-based segmentation and vascular tracing. TfR1 was quantified using ELISA. RI7217 antibodies were conjugated with 1.4 nm nanogold and brain uptake quantified using ICP-MS. ID significantly reduced the iron content in the capillary fraction, liver, spleen, kidney, heart, and skeletal muscles. ID increased the copper content in the brain. Analysis of cerebral cortical angioarchitecture revealed no chan
Paper identifies loss of transferrin and transferrin receptor in Alzheimer's disease hippocampus, which suppor… MEDIUM▼
Calcium and iron are essential bioelements regulating neuronal function and survival. Dysregulation of calcium signaling and iron homeostasis is implicated in Alzheimer's disease (AD), contributing to oxidative stress, synaptic dysfunction, and neurodegeneration. Previously, using in vitro cell-based models and transgenic mice, we demonstrated that CAMKK2, a calcium/calmodulin-dependent protein kinase, regulates iron transport via transferrin (TF) and transferrin receptor (TFRC). While excessive
✗ Opposing Evidence 7
Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies Pathways for Host-Directed Th… LOW▼
SPM immunomodulation may impair infection responses
TfR targeting may deliver payloads to proliferating tumor cells
Safety concern for systemic SPM overexposure
Pharmacokinetic challenge for TfR shuttle platforms
Septic cardiomyopathy is a severe cardiovascular disease with a poor prognosis. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy. SGLT2 inhibitors such as dapagliflozin have been demonstrated to improve ischemia-reperfusion injury by alleviating ferroptosis in cardiomyocyte. However, the role of dapagliflozin in sepsis remains unclear. Therefore, our study aims to investigate the therapeutic effects of dapagliflozin on LPS-induced septic cardiomyopathy. Our results indicate that dapagliflozin improved cardiac function in septic cardiomyopathy experimental mice. Mechanistically, dapagliflozin works by inhibiting the translation of key proteins involved in ferroptosis, such as GPX4, FTH1, and SLC7A11. It also reduces the transcription of lipid peroxidation-related mRNAs, including PTGS2 and ACSL4, as well as iron metabolism genes TFRC and HMOX1.
Cadmium exposure is associated with impaired ovarian function: Potential role of cadmium-induced ferroptosis i… MEDIUM▼
Cadmium (Cd) is a toxic environmental heavy metal with potential toxicity on the reproductive system. Cd-induced effects on ovarian function and the underlying mechanisms are unclear. This study integrated population-based and in vitro experiments to investigate the associations between environmental Cd exposure and ovarian dysfunction in reproductive-age women with infertility, and elucidated the potential molecular mechanisms involved. Elevated Cd exposure was significantly associated with lower serum estradiol levels and an inverted U-shaped relationship with anti-Müllerian hormone levels, suggesting diminished ovarian reserve. No significant associations were observed between Cd concentrations and in vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI) pregnancy outcomes. In vitro, Cd exposure dose-dependently impaired proliferation of KGN granulosa cells and induced cell death. Ferroptosis was characterized by GPX4 depletion, TFRC/ACSL4 upregulation, oxidative stress, lipid peroxidation, and Fe²⁺ accumulation, which were mitigated by the ferroptosis inhibitor ferrostatin-1. These findings suggest that environmental Cd exposure is associated with changes in levels of indicators of reduced ovarian reserve. Furthermore, Cd induces ferroptosis in granulosa cells in vitro, suggesting a plausible mechanistic link, highlighting a potential target for reducing environmental reproductive toxicity.
Valproic acid (VPA), a common antiepileptic drug, can cause liver steatosis after long-term therapy. However, an impact of ferroptosis on VPA-induced liver steatosis has not been investigated. In the study, treatment with VPA promoted ferroptosis in the livers of mice by elevating ferrous iron (Fe2+) levels derived from the increased absorption by transferrin receptor 1 (TFR1) and the decreased storage by ferritin (FTH1 and FTL), disrupting the redox balance via reduced levels of solute carrier family 7 member 11 (SLC7A11), glutathione (GSH), and glutathione peroxidase 4 (GPX4), and augmenting acyl-CoA synthetase long-chain family member 4 (ACSL4) -mediated lipid peroxide generation, accompanied by enhanced liver steatosis. All the changes were significantly reversed by co-treatment with an iron-chelating agent, deferoxamine mesylate (DFO) and a ferroptosis inhibitor, ferrostatin-1 (Fer-1). Similarly, the increases in Fe2+, TFR1, and ACSL4 levels, as well as the decreases in GSH, GPX4, and ferroportin (FPN) levels, were detected in VPA-treated HepG2 cells. These changes were also attenuated after co-treatment with Fer-1. It demonstrates that ferroptosis promotes VPA-induced liver steatosis through iron overload, inhibition of the GSH-GPX4 axis, and upregulation of ACSL4. It offers a potential therapy targeting ferroptosis for patients with liver steatosis following VPA treatment.
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Neuroinflammation Resolution
1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
Description: Synthetic super-agonists of GPR32 (RvD1 receptor) could restore microglial phagocytic capacity for clearing protein aggregates and apoptotic neurons. Enhanced efferocytosis would break the cycle of failed clearance that perpetuates chronic neuroinflammation in neurodegeneration.Target: GPR32 (CMKLR1) receptor and downstream PI3K/Akt signaling
Supporting Evidence: GPR32 activation promotes microglial M2 polarization (PMID: 27432871). Def
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.
1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
Specific Weaknesses:
- GPR32 expression varies dramatically across brain regions and disease states - superagonists may cause region-specific toxicity
- The cited RvD1/Aβ clearance study (PMID: 28814792) used systemic administration with unclear CNS penetration
- "Superagonists" implies supraphysiological activation that could trigger receptor desensitization or adverse downstream effects
- No evidence that GPR32
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
Practical Feasibility Assessment: Neuroinflammation Resolution Hypotheses
1. Microglial Efferocytosis Enhancement via GPR32 Superagonists
Druggability Assessment: MODERATE
- Target: GPR32 (CMKLR1) is a Class A GPCR - well-established druggable class
- Chemical Matter: Limited but emerging
- Existing compounds: Resolvin D1 (natural ligand, poor stability)
- Synthetic analogs: AT-RvD1 (aspirin-triggered RvD1), more stable
- Tool compounds: CMKLR1 selective agonists from Amgen (unpublished)
Competitive Landscape:
- Direct competitors: None in clin
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| ⚖ | Recalibrated | $0.554 | ▼ 0.5% | market_dynamics | 2026-04-13 03:33 |
| 📄 | New Evidence | $0.557 | ▲ 1.1% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.551 | ▲ 1.2% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.545 | ▼ 0.2% | 2026-04-12 18:34 | |
| ⚖ | Recalibrated | $0.546 | ▲ 0.8% | 2026-04-12 10:15 | |
| ⚖ | Recalibrated | $0.542 | ▼ 1.6% | 2026-04-12 05:13 | |
| ⚖ | Recalibrated | $0.550 | ▼ 0.5% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.553 | ▲ 0.6% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.550 | ▲ 0.5% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.547 | ▲ 2.2% | 2026-04-06 04:04 | |
| ⚖ | Recalibrated | $0.535 | ▼ 0.6% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.538 | 2026-04-04 16:02 | ||
| 📄 | New Evidence | $0.538 | ▲ 1.4% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.531 | ▼ 27.5% | 2026-04-03 23:46 | |
| 📄 | New Evidence | $0.733 | ▲ 0.5% | evidence_batch_update | 2026-04-03 01:06 |
Clinical Trials (11) Relevance: 69%
Active
Completed
Total Enrolled
Highest Phase
📚 Cited Papers (45)
📓 Linked Notebooks (1)
Wiki Pages
KG Entities (47)
Dependency Graph (3 upstream, 1 downstream)
Linked Experiments (9)
Related Hypotheses
Estimated Development
🧪 Falsifiable Predictions (21)
Knowledge Subgraph (140 edges)
associated with (7)
co associated with (21)
encodes (6)
implicated in (7)
mediates (2)
participates in (7)
promotes (1)
resolves (1)
Mechanism Pathway for TFRC
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
TFRC["TFRC"] -->|encodes| transferrin_receptor["transferrin_receptor"]
TFRC_1["TFRC"] -->|associated with| neurodegeneration["neurodegeneration"]
TFRC_2["TFRC"] -->|participates in| Transferrin_receptor___BB["Transferrin receptor / BBB transcytosis"]
BMAL1["BMAL1"] -->|co discussed| TFRC_3["TFRC"]
ALOX15["ALOX15"] -->|co discussed| TFRC_4["TFRC"]
CLOCK["CLOCK"] -->|co discussed| TFRC_5["TFRC"]
TFRC_6["TFRC"] -->|co discussed| GPR37["GPR37"]
TFRC_7["TFRC"] -->|co discussed| CMKLR1["CMKLR1"]
TFRC_8["TFRC"] -->|co discussed| ALOX12["ALOX12"]
TFRC_9["TFRC"] -->|co discussed| ALOX5["ALOX5"]
BCL2L1["BCL2L1"] -->|co discussed| TFRC_10["TFRC"]
CMKLR1_11["CMKLR1"] -->|co discussed| TFRC_12["TFRC"]
ALOX12_13["ALOX12"] -->|co discussed| TFRC_14["TFRC"]
ALOX5_15["ALOX5"] -->|co discussed| TFRC_16["TFRC"]
GPR37_17["GPR37"] -->|co discussed| TFRC_18["TFRC"]
style TFRC fill:#ce93d8,stroke:#333,color:#000
style transferrin_receptor fill:#4fc3f7,stroke:#333,color:#000
style TFRC_1 fill:#ce93d8,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style TFRC_2 fill:#ce93d8,stroke:#333,color:#000
style Transferrin_receptor___BB fill:#81c784,stroke:#333,color:#000
style BMAL1 fill:#ce93d8,stroke:#333,color:#000
style TFRC_3 fill:#ce93d8,stroke:#333,color:#000
style ALOX15 fill:#ce93d8,stroke:#333,color:#000
style TFRC_4 fill:#ce93d8,stroke:#333,color:#000
style CLOCK fill:#ce93d8,stroke:#333,color:#000
style TFRC_5 fill:#ce93d8,stroke:#333,color:#000
style TFRC_6 fill:#ce93d8,stroke:#333,color:#000
style GPR37 fill:#ce93d8,stroke:#333,color:#000
style TFRC_7 fill:#ce93d8,stroke:#333,color:#000
style CMKLR1 fill:#ce93d8,stroke:#333,color:#000
style TFRC_8 fill:#ce93d8,stroke:#333,color:#000
style ALOX12 fill:#ce93d8,stroke:#333,color:#000
style TFRC_9 fill:#ce93d8,stroke:#333,color:#000
style ALOX5 fill:#ce93d8,stroke:#333,color:#000
style BCL2L1 fill:#ce93d8,stroke:#333,color:#000
style TFRC_10 fill:#ce93d8,stroke:#333,color:#000
style CMKLR1_11 fill:#ce93d8,stroke:#333,color:#000
style TFRC_12 fill:#ce93d8,stroke:#333,color:#000
style ALOX12_13 fill:#ce93d8,stroke:#333,color:#000
style TFRC_14 fill:#ce93d8,stroke:#333,color:#000
style ALOX5_15 fill:#ce93d8,stroke:#333,color:#000
style TFRC_16 fill:#ce93d8,stroke:#333,color:#000
style GPR37_17 fill:#ce93d8,stroke:#333,color:#000
style TFRC_18 fill:#ce93d8,stroke:#333,color:#000
3D Protein Structure
🧬 TFRC — PDB 1CX8 Click to expand 3D viewer
Source Analysis
Neuroinflammation resolution mechanisms and pro-resolving mediators
neurodegeneration | 2026-04-01 | completed